Human Longevity Secures $30 Million Funding to Enhance Health Nucleus AI Platform

VCBeat (WeChat ID: vcbeat) learned from foreign media that on November 6, 2019, local time, Human Longevity, Inc. (HLI), a medical artificial intelligence company headquartered in San Diego, California, announced it had secured $30 million in financing. This round was jointly invested by existing investor Emerging Technology Partners and other new investors focused on the healthcare sector.

Prior to this, Human Longevity completed its Series A and Series B financing rounds on March 4, 2014, and April 5, 2016, respectively.

"This round of financing will be used to strengthen the construction of the Health Nucleus intelligent platform under Human Longevity."

Human Longevity, founded in 2013 by leaders in the field of genomics, is a medical artificial intelligence company grounded in genomic research. The company’s ultimate goal is to ensure that every patient has access to data-driven, precise health intelligence. As an innovator providing a data-driven precision health intelligence platform for physicians and patients, Human Longevity combines the largest database of genomic and phenotypic data with machine learning to drive discovery, revolutionize medical practice, enhance the proactive nature of healthcare, and improve patients’ lives.

Health Nucleus is a medical intelligence platform under Human Longevity. The platform leverages magnetic resonance imaging, whole-genome sequencing, and other laboratory tests, along with machine learning and AI-derived integrated metrics, to establish comprehensive standards for assessing patients’ health and performance.

HLI combines state-of-the-art DNA sequencing and expert analysis with machine learning to help transform medicine into a data-driven science. Through Health Nucleus assessments, Human Longevity provides patients with unparalleled, precise health analytics. By sequencing an individual’s entire genome using machine learning and artificial intelligence, and conducting comprehensive evaluations via magnetic resonance imaging (MRI), cardiac CT scans, metabolic testing, and other methods, the company delivers risk analyses for heart disease, cancer, metabolic disorders, and cognitive issues.

Notably, within the traditional healthcare system in China, while medical centers across the country are equipped with magnetic resonance imaging (MRI) scanners, it is virtually impossible for patients to undergo whole-body MRI scans unless they have a serious medical condition. In contrast, Health Nucleus performs whole-body MRI scans on patients and generates personalized reports.

In the medical community, most age-related chronic diseases—such as the emergence of new tumors, elevated hepatic fat fraction, arrhythmias, and cardiac conduction abnormalities—are difficult to detect in a timely manner, leading to many patients losing their lives after the age of 50. Health Nucleus helps patients detect these conditions before symptoms appear. Through the Health Nucleus platform, patients can promptly understand their health status and receive comprehensive evaluation reports. These personalized health reports provide patients with the information needed to make informed, proactive decisions, such as determining the optimal frequency for cancer screening and assessing whether reducing body mass index can maximally lower the risk of Alzheimer’s disease.

Emerging Technology Partners (ETP), founded in 2000 and headquartered in San Francisco, California, is a life sciences-focused investment firm specializing in cross-border investments. ETP is dedicated to providing capital to companies in the life sciences sector and assisting them in the manufacturing of medical products. The firm has investment partners in Boston, San Francisco, Washington, D.C., and Beijing.

(Compiled by Wang Fang)